Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)

Tomas Kauer - Moderator

Oct 1, 2024 - 04:00

Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)

Tags:

Previous Article

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B P...

The PG&E Corporation Foundation and California Fire Foundation Announce Wildfire...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Tomas Kauer - Moderator

Related Posts

NZ's Auckland Intl Airport to raise $861.8 million, signs contract to build new terminal

NZ's Auckland Intl Airport to raise $861.8 million, sig...

Tomas Kauer - Mode... Sep 16, 2024

Israel kills Hezbollah leader Nasrallah, robbing Iran of top ally

Israel kills Hezbollah leader Nasrallah, robbing Iran o...

Tomas Kauer - Mode... Sep 29, 2024

Chemed corp director Walsh sells shares worth nearly $239k

Chemed corp director Walsh sells shares worth nearly $239k

Tomas Kauer - Mode... Sep 28, 2024